Patent intelligence · US
US 11613739
Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells
Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells
Patent details — US 11613739
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 28, 2023
- Expiration
- Mar 23, 2043
- Applicant
- REGENXBIO INC.
- Claims
- 16
- CPC classes
- A61K, A61K35/76, A61K38/00, A61K47/26
Quick answer
US 11613739 (Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells) is held by REGENXBIO INC.. Status: granted. Granted Mar 28, 2023. Expires Mar 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENXBIO INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K35/76, A61K38/00, A61K47/26, A61K48/00, A61K48/005
More from REGENXBIO INC.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11613739?
US 11613739 (Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells) is held by REGENXBIO INC.. Status: granted. Granted Mar 28, 2023. Expires Mar 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11613739?
REGENXBIO INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11613739 expire?
Our index shows an expiration date of Mar 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.